Celgene Revlimid user fee extension
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's action date for Celgene's myelodysplastic syndromes treatment Revlimid (lenalidomide) is Jan. 7 following a 90-day extension to allow further review of the firm's risk management program. Celgene's submission of "additional information" on its RevAssist RMP "has been considered by the FDA to be a major amendment to the Revlimid NDA," Celgene says Oct. 3. The extension comes on the heels of Celgene's Sept. 28 announcement that it has suspended a Phase III multiple myeloma trial after patients developed blood clots. The firm said the trial would resume within weeks after amending the protocol to include aspirin. A multiple myeloma NDA is slated for November...
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.